Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors

被引：0
|
作者：
Karima Saboundji
Jean-Bernard Auliac
Maurice Pérol
Géraldine François
Henri Janicot
Marie Marcq
Catherine Dubos-Arvis
Aldo Renault
Florian Guisier
Luc Odier
Radj Gervais
Christos Chouaïd
机构：
[1] CH François-Quesnay,Pneumologie et Oncologie Thoracique
[2] Centre Léon-Bérard,Oncologie
[3] CHU d’Amiens,Pneumologie et Oncologie Thoracique
[4] CHU Clermont-Ferrand,Pneumologie
[5] CHU Vendée,Pneumologie
[6] Centre François-Baclesse,Oncologie
[7] CH François-Mitterrand,Pneumologie
[8] CHU Charles-Nicolle,Pneumologie
[9] Hôpital Nord-Ouest,Pneumologie
[10] CH Intercommunal de Créteil,Pneumologie
来源：
Targeted Oncology | 2018年 / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：501 / 507
页数：6
相关论文
共 50 条
  • [1] Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
    Saboundji, Karima
    Auliac, Jean-Bernard
    Perol, Maurice
    Francois, Geraldine
    Janicot, Henri
    Marcq, Marie
    Dubos-Arvis, Catherine
    Renault, Aldo
    Guisier, Florian
    Odier, Luc
    Gervais, Radj
    Chouaid, Christos
    TARGETED ONCOLOGY, 2018, 13 (04) : 501 - 507
  • [2] Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases
    Flippot, R.
    Auclin, E.
    Biondani, P.
    Le Rhun, E.
    Adam, J.
    Planchard, D.
    Caramella, C.
    Le Pechoux, C.
    Lacroix, L.
    Gazzah, A.
    Mezquita, L.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S467 - S467
  • [3] Leptomeningeal metastases in EGFR-mutated non-small cell lung carcinoma: Management after tyrosine kinase inhibitors
    Flippot, R.
    Auclin, E.
    Biondani, P.
    Le Rhun, E.
    Planchard, D.
    Caramella, C.
    Le Pechoux, C.
    Lacroix, L.
    Mezquita, L.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S85 - S86
  • [4] Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases
    Tamura, K.
    Yoshida, T.
    Masuda, K.
    Matsumoto, Y.
    Shinno, Y.
    Okuma, Y.
    Goto, Y.
    Horinouchi, H.
    Yamamoto, N.
    Ohe, Y.
    ESMO OPEN, 2023, 8 (04)
  • [5] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Roviello, Giandomenico
    Zanotti, Laura
    Cappelletti, Maria Rosa
    Gobbi, Angela
    Dester, Martina
    Paganini, Giovanni
    Pacifico, Chiara
    Generali, Daniele
    Roudi, Raheleh
    CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (01) : 15 - 20
  • [6] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Giandomenico Roviello
    Laura Zanotti
    Maria Rosa Cappelletti
    Angela Gobbi
    Martina Dester
    Giovanni Paganini
    Chiara Pacifico
    Daniele Generali
    Raheleh Roudi
    Clinical and Experimental Medicine, 2018, 18 : 15 - 20
  • [7] Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence
    Flippot, R.
    Auclin, E.
    Biondani, P.
    Le Rhun, E.
    Adam, J.
    Planchard, D.
    Caramella, C.
    Le Pechoux, C.
    Lacroix, L.
    Gazzah, A.
    Mezquita, L.
    Besse, B.
    ANNALS OF ONCOLOGY, 2018, 29 : 523 - 523
  • [8] Progression of leptomeningeal metastases in advanced EGFR-mutated non-small cell lung cancer
    Zhao, Q.
    Deng, L.
    Zhang, Y.
    Zhou, X.
    Li, Y.
    Yu, M.
    Zhou, L.
    Zou, B.
    Liu, Y.
    Lu, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis
    Wu, Haicheng
    Zhang, Qian
    Zhai, Wanchen
    Chen, Yunfei
    Yang, Yehao
    Xie, Mingning
    Huang, Zhiyu
    Xu, Yanjun
    Li, Hui
    Gong, Lei
    Yu, Sizhe
    Fan, Yun
    Chen, Kaiyan
    LUNG CANCER, 2024, 188
  • [10] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
12345